- Home
- PCRX vs SEAT Comparison
PCRX vs SEAT Comparison
Compare PCRX & SEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- SEAT
- Stock Information
- Founded
- PCRX 2006
- SEAT 2001
- Country
- PCRX United States
- SEAT United States
- Employees
- PCRX N/A
- SEAT N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- SEAT Industrial Machinery/Components
- Sector
- PCRX Health Care
- SEAT Industrials
- Exchange
- PCRX Nasdaq
- SEAT Nasdaq
- Market Cap
- PCRX 1.2B
- SEAT 366.2M
- IPO Year
- PCRX 2011
- SEAT N/A
- Fundamental
- Price
- PCRX $22.90
- SEAT $1.81
- Analyst Decision
- PCRX Buy
- SEAT Buy
- Analyst Count
- PCRX 8
- SEAT 11
- Target Price
- PCRX $28.38
- SEAT $4.49
- AVG Volume (30 Days)
- PCRX 545.0K
- SEAT 1.4M
- Earning Date
- PCRX 07-29-2025
- SEAT 08-05-2025
- Dividend Yield
- PCRX N/A
- SEAT N/A
- EPS Growth
- PCRX N/A
- SEAT N/A
- EPS
- PCRX N/A
- SEAT N/A
- Revenue
- PCRX $702,772,000.00
- SEAT $748,757,000.00
- Revenue This Year
- PCRX $7.54
- SEAT N/A
- Revenue Next Year
- PCRX $10.78
- SEAT $4.42
- P/E Ratio
- PCRX N/A
- SEAT N/A
- Revenue Growth
- PCRX 3.08
- SEAT 0.82
- 52 Week Low
- PCRX $11.16
- SEAT $1.44
- 52 Week High
- PCRX $27.64
- SEAT $5.74
- Technical
- Relative Strength Index (RSI)
- PCRX 35.82
- SEAT 48.12
- Support Level
- PCRX $22.82
- SEAT $1.82
- Resistance Level
- PCRX $23.83
- SEAT $2.06
- Average True Range (ATR)
- PCRX 0.74
- SEAT 0.14
- MACD
- PCRX -0.02
- SEAT 0.02
- Stochastic Oscillator
- PCRX 6.22
- SEAT 45.65
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.